Verify patient identity, confirm absence of contraindications such as bowel perforation, perform standard coagulation profile review, ensure informed consent, and verify endoscopic equipment readiness. Minimal sedation or topical oropharyngeal anesthesia as required.
Patient to remain under observation for 30-60 minutes post-procedure. Monitor vital signs for stability. Clear liquid diet may resume after anesthesia wears off. Discharge permitted if stable; follow-up scheduled for 2-4 weeks or as clinically indicated.
Comprehensive Clinical Guide: Endoscopic Hemostasis via Hemospray (TC-325)
1. Introduction and Clinical Overview
In the field of interventional gastroenterology, the management of acute non-variceal upper gastrointestinal bleeding (NVUGIB) remains a high-stakes challenge. Among the technological advancements designed to address this, the Hemospray (TC-325) system stands out as a revolutionary non-contact, mineral-based hemostatic agent.
Unlike traditional mechanical methods (clips, bands) or thermal methods (coagulation probes), Hemospray functions through a physical mechanism of action. It is a highly absorbent, inorganic powder that, upon contact with blood, creates a mechanical barrier to stop bleeding. This guide serves as an authoritative resource for clinicians, nurses, and medical staff on the application, safety, and clinical utility of this device.
2. Technical Specifications and Mechanism of Action
The Hemospray system consists of a specialized delivery catheter and a canister of TC-325 powder (a proprietary mineral blend).
Mechanism of Action (The "Physical Seal")
The efficacy of TC-325 is predicated on three distinct physiological interactions:
1. Rapid Absorption: The powder rapidly absorbs water from the blood, concentrating clotting factors, platelets, and fibrinogen at the site of the bleed.
2. Mechanical Barrier: Once hydrated, the powder transforms into a cohesive, adhesive, and durable gel-like coagulum that physically plugs the bleeding vessel.
3. Coagulation Cascade Acceleration: By concentrating the blood components, it significantly accelerates the natural coagulation process.
Delivery System Specifications
- Catheter Compatibility: Designed for use with standard endoscopes (typically 3.2mm or larger accessory channels).
- Propellant: Utilizes CO2 (carbon dioxide) to propel the powder, ensuring the system is non-flammable and safe for use with electrocautery.
- Non-Contact Delivery: The powder is sprayed onto the site, making it ideal for diffuse bleeding where the specific bleeding vessel may be difficult to target with mechanical clips.
3. Clinical Indications and Usage
Hemospray is indicated for the treatment of non-variceal upper gastrointestinal bleeding. Its primary utility lies in its ability to manage diffuse or large-surface-area bleeding where traditional methods fail.
Primary Indications
- Peptic Ulcer Disease: Specifically for Forrest Ia and Ib ulcers.
- Malignancy-Related Bleeding: Managing oozing from friable tumor surfaces.
- Post-Procedural Bleeding: Hemostasis following EMR (Endoscopic Mucosal Resection) or ESD (Endoscopic Submucosal Dissection).
- Diffuse Bleeding: Lesions where precise targeting of a vessel is anatomically impossible.
- Bridge Therapy: Acting as a temporizing measure for patients who are hemodynamically unstable while awaiting definitive surgical or interventional radiological intervention.
Clinical Comparison Table: Hemospray vs. Traditional Methods
| Feature | Hemospray (TC-325) | Mechanical Clips | Thermal Coagulation |
|---|---|---|---|
| Contact Requirement | Non-Contact | Direct Contact | Direct Contact |
| Bleeding Type | Diffuse/Oozing | Focal/Arterial | Focal/Arterial |
| Targeting Precision | Low | High | High |
| Ease of Use | High | Moderate | Moderate |
| Tissue Damage Risk | Minimal | Moderate (perforation risk) | High (thermal injury) |
4. Patient Preparation and Procedure Steps
Pre-Operative Preparation
- Resuscitation: Prior to endoscopy, ensure the patient is hemodynamically stabilized with fluids and/or blood products.
- Consent: Obtain informed consent acknowledging the off-label potential or specific procedure risks.
- Anticoagulation: Evaluate the need for reversal of anticoagulants if clinically feasible.
- Equipment Check: Verify the CO2 canister is connected correctly and the catheter is patent.
The Intervention Protocol
- Endoscopic Visualization: Identify the bleeding site. Perform irrigation to clear the visual field of blood and clots.
- Catheter Positioning: Advance the Hemospray catheter through the accessory channel. Maintain a distance of 1–2 cm from the target tissue to ensure proper distribution.
- Application: Depress the actuator in short, controlled bursts. Observe the formation of the greyish-white coagulum.
- Observation: Monitor for 3–5 minutes post-application to ensure the hemostatic seal is stable.
- Documentation: Record the amount of powder used and the visual success of the hemostasis.
5. Post-Operative Recovery and Monitoring
Post-procedural care is critical to preventing re-bleeding.
- Monitoring: Patients should be monitored in a high-dependency unit (HDU) or ICU for at least 24 hours, depending on the severity of the initial bleed.
- Diet: NPO (nothing by mouth) for the first 6–12 hours, followed by a gradual progression to a liquid or soft diet.
- Medication: High-dose Proton Pump Inhibitor (PPI) therapy (e.g., IV Pantoprazole) is mandatory to promote ulcer healing and prevent premature dissolution of the coagulum.
- Follow-up: Repeat endoscopy is generally not required unless there is clinical evidence of recurrent bleeding (e.g., melena, hematemesis, drop in hemoglobin).
6. Risks, Side Effects, and Contraindications
Potential Complications
- Embolism: While rare, there is a theoretical risk of powder entering the bloodstream if a large vessel is open.
- Obstruction: Excessive powder accumulation can cause temporary luminal obstruction.
- Perforation: Usually associated with the physical trauma of the catheter tip rather than the powder itself.
- Recurrent Bleeding: The coagulum naturally sloughs off within 24–48 hours; if the underlying ulcer has not begun to heal, re-bleeding may occur.
Contraindications
- Active Variceal Bleeding: Hemospray is not indicated for varices (e.g., esophageal varices), as it does not address the underlying portal hypertension and may be ineffective against high-pressure arterial flow.
- Known Allergy: Hypersensitivity to mineral-based powders (extremely rare).
- Anatomical Obstruction: Where the powder cannot be delivered safely to the target site.
7. Alternative Treatments
While Hemospray is a powerful tool, it should be part of a multimodal strategy. Alternative treatments include:
1. Mechanical Hemostasis: Hemoclips are the gold standard for visible, spurting vessels.
2. Thermal Therapy: Bipolar coagulation or heater probes.
3. Injection Therapy: Epinephrine (1:10,000) injection to induce vasoconstriction.
4. Surgical Intervention: The ultimate salvage therapy for cases refractory to all endoscopic measures.
8. Massive FAQ Section
Q1: Can Hemospray be used on esophageal varices?
A: No. Hemospray is not indicated for variceal bleeding. Band ligation or sclerotherapy is the standard of care for varices.
Q2: How long does the Hemospray barrier last?
A: The coagulum typically dissolves or sloughs off within 24 to 48 hours, providing a critical window for the ulcer to stabilize.
Q3: Is the powder toxic if ingested?
A: No, the powder is biocompatible and inert. It passes through the gastrointestinal tract without systemic absorption.
Q4: Can I use Hemospray with a 2.8mm scope channel?
A: Most Hemospray catheters require at least a 3.2mm channel. Always check the manufacturer's compatibility chart for your specific endoscope model.
Q5: What happens if the powder gets into the airway?
A: Extreme care must be taken during suctioning. If the patient is intubated, ensure the cuff is inflated. If not, maintain a clear view of the airway to prevent aspiration.
Q6: Does the powder expire?
A: Yes, each canister has a shelf-life and expiration date. Ensure compliance with the manufacturer’s storage guidelines.
Q7: Can I use Hemospray in combination with other treatments?
A: Yes, it is frequently used as a "rescue" therapy when standard mechanical methods fail.
Q8: Is the procedure painful for the patient?
A: The procedure is performed under sedation or general anesthesia, so the patient will not experience pain.
Q9: What should I do if the catheter clogs?
A: Do not force the actuator. Withdraw the catheter, flush with air, or replace the catheter if the clog persists.
Q10: Is Hemospray effective for tumors?
A: Yes, it is highly effective for managing diffuse oozing from friable, malignant tissue where clip placement is impossible due to tissue necrosis.
9. Conclusion
The Hemospray (TC-325) system represents a significant shift toward "non-contact" hemostasis. By leveraging the physical properties of mineral-based powders, clinicians can achieve rapid, effective control of bleeding in complex scenarios. However, it must be emphasized that Hemospray is a tool for stabilization—not a replacement for underlying surgical or medical management of the patient's primary pathology. Expert clinical judgment, combined with a thorough understanding of the device’s limitations, ensures the best possible patient outcomes.
Disclaimer: This guide is intended for educational purposes for healthcare professionals. Always refer to the specific manufacturer’s Instructions for Use (IFU) and institutional clinical protocols before performing any medical procedure.